{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:07Z","timestamp":1790790847329,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to comparatively assess the risk of cardiovascular events (CVEs) in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) and to explore the interactions with patient profiles [including age, baseline cardiovascular (CV) risk, and frailty, which is a state of decreased physiological reserve, assessed using a validated frailty index (FI) for healthcare administrative databases (AHDs)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study was based on AHDs of the Lombardy region, Italy (from 1st January 2020 to 31st December 2023). Cox regression models, both crude and adjusted, were applied to estimate the association between treatments and outcomes [CVEs, major adverse cardiovascular events (MACEs), and thromboembolic events (TEs)]. We tested the interaction between the drug treatment and the regulatory agency prescription rule changes [before or after 06th July 2021, the date of the first European Medicine Association (EMA) pronouncement on tofacitinib safety] or patient profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 7,541 therapeutic courses in 5,563 patients: 2,343 started as TNFi users, 1,443 as JAKi users, and 1,777 started with other drugs (1,459 days of follow-up). The crude incidence rates (IRs) for new CVEs were 16.6 [95% confidence intervals (95% CI): 12.8\u201321.2] and 18.6 (95% CI: 14.2\u201323.9) per 1,000 person-years (PYs) for TNFi and JAKi users, respectively. Exposure to JAKis was not associated with a significantly increased risk of CVEs [adjusted hazard ratio (HR): 0.92; 95% CI: 0.64\u20131.32], MACEs (adjusted HR: 0.71; 95% CI: 0.37\u20131.33), or TEs (adjusted HR: 1.53; 95% CI: 0.65\u20133.65) compared to TNFis. Each 0.1-point increment of the FI significantly increased the HR for new CVEs (HR: 1.80; 95% CI: 1.48\u20132.19), MACEs (HR: 1.66; 95% CI: 1.10\u20132.51), and TEs (HR: 1.69; 95% CI: 1.03\u20132.78). When assessing the interaction between the period of drug delivery and the treatment with JAKis on the risk of new CVEs, no significant interaction was observed (p = 0.838), while the interaction was statistically significant for baseline CV risk (p = 0.007).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RA patients treated with JAKis in real-world settings have a risk of developing CVEs no higher than those of TNFi users, but potential signals remain for TEs, even if the sample was not sufficiently powered. Patient profiles, particularly the frailty, have a more substantial impact on the risk of CVEs than the specific disease-modifying anti-rheumatic drug (DMARD) choice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1565909","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:24:46Z","timestamp":1745544286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles"],"prefix":"10.3389","volume":"16","author":[{"given":"Ettore","family":"Silvagni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Occhino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Garaffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Delvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Scir\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rebora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.55563\/clinexprheumatol\/ins2z2","article-title":"Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs","volume":"41","author":"Ahn","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"745601","DOI":"10.3389\/fmed.2021.745601","article-title":"Rheumatoid arthritis and cardiovascular risk: retrospective matched-cohort analysis based on the RECORD study of the Italian society for rheumatology","volume":"8","author":"Argnani","year":"2021","journal-title":"Front. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","article-title":"Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study)","volume":"83","author":"Aymon","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/joim.20014","article-title":"Delirium and frailty in older adults: clinical overlap and biological underpinnings","volume":"296","author":"Bellelli","year":"2024","journal-title":"J. Intern. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s10072-023-06885-8","article-title":"Assessing frailty at the centers for dementia and cognitive decline in Italy: potential implications for improving care of older people living with dementia","volume":"44","author":"Bellelli","year":"2023","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLOS Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/jpm13091303","article-title":"ReLiFiRa (real life filgotinib in rheumatoid arthritis): retrospective study of efficacy and safety in common clinical practice","volume":"13","author":"Benucci","year":"2023","journal-title":"J. Pers. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e003630","DOI":"10.1136\/rmdopen-2023-003630","article-title":"Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis","volume":"9","author":"Bower","year":"2023","journal-title":"RMD Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4212\/cjhp.v68i3.1457","article-title":"An introduction to health care administrative data","volume":"68","author":"Cadarette","year":"2015","journal-title":"Can. J. Hosp. Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.42846","article-title":"Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol. Hob. N. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/art.42928","article-title":"Association of cardiovascular outcomes with low-dose glucocorticoid prescription in patients with rheumatoid arthritis","volume":"76","author":"Coburn","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1421328","DOI":"10.3389\/fmed.2024.1421328","article-title":"Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action","volume":"11","author":"Corrao","year":"2024","journal-title":"Front. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0218919","DOI":"10.1371\/journal.pone.0218919","article-title":"A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project","volume":"14","author":"Cozzolino","year":"2019","journal-title":"PLoS ONE"},{"key":"B16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","article-title":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study","volume":"61","author":"Desai","year":"2022","journal-title":"Rheumatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B18","article-title":"Janus kinase inhibitors (JAKi)","year":"2022","journal-title":"Eur. Med. Agency"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1225160","DOI":"10.3389\/fimmu.2023.1225160","article-title":"The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events","volume":"14","author":"Favalli","year":"2023","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"105343","DOI":"10.1016\/j.jbspin.2022.105343","article-title":"Frailty in rheumatoid arthritis: a systematic review and meta-analysis","volume":"89","author":"Gao","year":"2022","journal-title":"Jt. Bone Spine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.55563\/clinexprheumatol\/1sjgyr","article-title":"Novel insights into the management of rheumatoid arthritis: one year in review 2022","volume":"40","author":"Garaffoni","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"B23","first-page":"310","article-title":"Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept","volume":"36","author":"Generali","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00228-022-03402-2","article-title":"JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study","volume":"78","author":"Gouverneur","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/sim.4048","article-title":"A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study","volume":"29","author":"Gran","year":"2010","journal-title":"Stat. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/rheumatology\/kead543","article-title":"Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"63","author":"Hayashi","year":"2023","journal-title":"Rheumatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s43587-021-00099-3","article-title":"The degree of frailty as a translational measure of health in aging","volume":"1","author":"Howlett","year":"2021","journal-title":"Nat. Aging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.19191\/EP19.4.S2.P037.091","article-title":"A systematic review of case-identification algorithms based on Italian healthcare administrative databases for three relevant diseases of the cardiovascular system: acute myocardial infarction, ischemic heart disease, and stroke","volume":"43","author":"Hyeraci","year":"2019","journal-title":"Epidemiol. Prev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.juro.2013.04.048","article-title":"Values and pitfalls of the use of administrative databases for outcomes assessment","volume":"190","author":"Johnson","year":"2013","journal-title":"J. Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J. Gerontol. A. Biol. Sci. Med. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2147\/CLEP.S402360","article-title":"Validation of an algorithm to identify venous thromboembolism in health insurance claims data among patients with rheumatoid arthritis","volume":"15","author":"Kim","year":"2023","journal-title":"Clin. Epidemiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3899\/jrheum.2023-0145","article-title":"Safety of janus kinase inhibitors: a real-world multicenter retrospective cohort study","volume":"50","author":"Lanzillotta","year":"2023","journal-title":"J. Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1370661","DOI":"10.3389\/fphar.2024.1370661","article-title":"Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients","volume":"15","author":"Ma","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e003489","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e2023045","DOI":"10.4178\/epih.e2023045","article-title":"Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data","volume":"45","author":"Min","year":"2023","journal-title":"Epidemiol. Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","article-title":"Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry","volume":"63","author":"Mok","year":"2023","journal-title":"Rheumatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"947","DOI":"10.55563\/clinexprheumatol\/166dsf","article-title":"Novel insights into the management of rheumatoid arthritis: one year in review 2024","volume":"42","author":"Molteni","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"576134","DOI":"10.3389\/fimmu.2020.576134","article-title":"Frailty in rheumatic diseases","volume":"11","author":"Motta","year":"2020","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/gerona\/gly232","article-title":"The burden of frailty among U.S. Veterans and its association with mortality, 2002\u20132012","volume":"74","author":"Orkaby","year":"2019","journal-title":"J. Gerontol. A. Biol. Sci. Med. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.200265","article-title":"The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"48","author":"Ozen","year":"2021","journal-title":"J. Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.31138\/mjr.171023.rof","article-title":"Risk of major adverse cardiovascular events and venous thromboembolism with JAK inhibitors versus TNF inhibitors in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"35","author":"Partalidou","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1093\/rheumatology\/kead531","article-title":"Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population","volume":"63","author":"Popa","year":"2023","journal-title":"Rheumatology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1134377","DOI":"10.3389\/fmed.2023.1134377","article-title":"Development and validation of an electronic database-based frailty index to predict mortality and hospitalization in a population-based study of adults with SARS-CoV-2","volume":"10","author":"Rebora","year":"2023","journal-title":"Front. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J. Gerontol. A. Biol. Sci. Med. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e003885","DOI":"10.1136\/rmdopen-2023-003885","article-title":"Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database","volume":"10","author":"Sakai","year":"2024","journal-title":"RMD Open"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s10067-019-04486-5","article-title":"Prevalence of frailty and its associated factors in patients with rheumatoid arthritis: a cross-sectional analysis","volume":"38","author":"Salaffi","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12016-022-08943-z","article-title":"Inflammaging and frailty in immune-mediated rheumatic diseases: how to address and score the issue","volume":"64","author":"Salaffi","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.clinthera.2021.06.008","article-title":"Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases","volume":"43","author":"Setyawan","year":"2021","journal-title":"Clin. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e021447","DOI":"10.1136\/bmjopen-2017-021447","article-title":"Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage on Rheumatic Diseases study on health care administrative databases","volume":"8","author":"Silvagni","year":"2018","journal-title":"BMJ Open"},{"key":"B56","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/acr.25282","article-title":"Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted-synthetic disease-modifying antirheumatic drugs","volume":"76","author":"Singh","year":"2024","journal-title":"Arthritis Care Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1445680","DOI":"10.3389\/fimmu.2024.1445680","article-title":"Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study","volume":"15","author":"Strunz","year":"2024","journal-title":"Front. Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/pds.2341","article-title":"A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data","volume":"21","author":"Tamariz","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol. Hob. N. J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/joim.13681","article-title":"Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study","volume":"294","author":"Tong","year":"2023","journal-title":"J. Intern. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1237234","DOI":"10.3389\/fphar.2023.1237234","article-title":"Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1267749","DOI":"10.3389\/fimmu.2023.1267749","article-title":"Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study","volume":"14","author":"Yoshida","year":"2023","journal-title":"Front. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1565909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:24:47Z","timestamp":1745544287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1565909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":64,"alternative-id":["10.3389\/fphar.2025.1565909"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1565909","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1565909"}}